研究单位：[1]Ruijin Hospital[2]Tongji Hospital Wuhan, Hubei, China[3]Jiangsu Province Hospital Nanjing, Jiangsu, China[4]The first hospital of China medical university Shenyang, Liaoning, China[5]Shanxi Provincial Tumor Hospital Taiyuan, Shanxi, China[6]West China Hospital Chengdu, Sichuan, China[7]Institute of Hematology and Blood Diseases Hospital Tianjin, Tianjin, China[8]Shandong Provincal Hospital Jinan, China[9]Shanghai Ruijin Hospital Shanghai, China, 200025[10]Southwest Hospital Chongqing, Chongqing, China[11]Fujian Medical University Union Hospital Fuzhou, Fujian, China[12]Guangdong General Hospital Guangzhou, Guangdong, China[13]Henan Cancer Hospital Zhengzhou, Henan, China
The main purpose of this study is to evaluate the safety and efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell lymphoma and Follicular Lymphoma Grade 3B patients.
